Immatics aims to transform cancer treatment by harnessing the power of the body’s own immune system to selectively attack and kill cancer cells by exploiting its unique capabilities to define currently unexploited intracellular T-cell targets.
Cancer immunotherapy has delivered impressive outcomes for patients over the past few years, yet the field is still severely constrained by the lack of novel targets. Immatics overcomes this by applying its target discovery engine XPRESIDENT® to identify and validate dozens of antigens specific to cancer cells.
These antigens, also called Tumor-Associated Peptides (TUMAPs), are selectively expressed (or highly overexpressed) on cancer tissues and are able to activate specialized immune cells called T cells which are responsible for identifying and destroying cancer cells. These well-characterized TUMAPs are the key to the range of various immunotherapy approaches being developed today. They can be used as targets for all of the most promising cancer immunotherapy approaches including Adoptive Cell Therapies (ACT), T cell receptor (TCR) and antibody (Ab) bispecifics as well as cancer vaccines. Immatics is actively developing programs in all of these areas.
Immatics Biotechnologies GmbH is based in Tübingen and Martinsried (Munich), Germany. Tübingen is the company’s head-quarter, driving all XPRESIDENT® target and TCR discovery efforts as well as the development of bispecifics.
Immatics US, Inc., based in Houston, TX, was launched in 2015 as a joint venture between Immatics GmbH and the world leading MD Anderson Cancer Center (MDACC) to focus on the development of next-generation ACT for the treatment of cancer. Immatics US, Inc.’s most advanced ACT approaches, ACTolog® and ACTengine®, are currently in pre-clinical development and will commence clinical development in 2017.
Immatics has entered into a number of strategic cancer immunotherapy collaborations to fully leverage the potential of XPRESIDENT®. Since November 2013 Roche and Immatics have committed to develop and commercialize a number of new cancer peptide antigen-based immunotherapies, targeting primarily gastric, prostate and non-small cell lung cancer. In 2015 Immatics and MorphoSys initiated a strategic alliance to develop antibody-based therapies targeting TUMAPs, and beginning January 2017, Amgen and Immatics will develop and commercialize novel TCR- and Ab-based bispecific cancer drugs. Together with academic and industry partners Immatics is also investigating a fully personalized cancer vaccine (GAPVAC) based on the patient’s tumor characteristics, a project which is funded by the EU.